RxDoctor Payments Data

Julia Schroeder, MD

Addiction Medicine · Louisville, KYNPI 1013901040

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Braeburn Inc. at 28.8% of the total. Reporting peaked in 2024 at $314 and has fallen 58.0% since, to $132 in 2025. That places this record below the midpoint for addiction medicine clinicians in KY, where the typical reported total is $695.

$695in general payments, 2019–2025

Across 38 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Braeburn Inc.$200
  • AbbVie$159
  • Indivior Inc.$133
  • Orexo US, Inc.$43
  • Hikma Pharmaceuticals USA$35
  • Vanda Pharmaceuticals Inc.$34
  • plus $89 from 4 others

What the payments were for

  • Food & beverage$66095%
  • Education$355%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$695 in reported general payments places this provider in the 50th percentile of 40 addiction medicine providers in Kentucky.

See all addiction medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$5,071
Medicare patients
19
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl144$17,671
Methylphenidate ErMethylphenidate Hcl25$3,458
Gabapentin64$576
Albuterol Sulfate HfaAlbuterol Sulfate17$426
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$259
Hydroxyzine Pamoate12$38
Fluoxetine Hcl11$33
Clonidine Hcl12$12

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine-Naloxone$35$17,671144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 40 addiction medicine providers in Kentucky.

Other addiction medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →